Next Article in Journal
Vitamin A Rich Diet Diminishes Early Urothelial Carcinogenesis by Altering Retinoic Acid Signaling
Previous Article in Journal
Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care
Previous Article in Special Issue
microRNAs and Markers of Neutrophil Activation as Predictors of Early Incidental Post-Surgical Pulmonary Embolism in Patients with Intracranial Tumors
Open AccessArticle

Single-Drug Approach with Edoxaban is Effective for Resolving Non-Acute Cancer-Associated Venous Thrombosis: A Single-Arm Retrospective Analysis

1
Medical Oncology, Showa University Koto Toyosu Hospital, 5-1-38 Toyosu, Koto-ku, Tokyo 135-8577, Japan
2
Medical Oncology, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tsuzuki-ku Yokohama-shi, Kanagawa 224-8503, Japan
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1711; https://doi.org/10.3390/cancers12071711
Received: 3 May 2020 / Revised: 19 June 2020 / Accepted: 24 June 2020 / Published: 28 June 2020
(This article belongs to the Special Issue Treatment of Cancer-Associated Thrombosis)
Recently, cancer-related venous thromboembolism (VTE) has been termed “cancer-associated thrombosis (CAT)” and is the focus of current research. We retrospectively investigated the efficacy of a single-drug approach with edoxaban for the treatment of non-acute CAT. Thirty-two non-acute CAT patients who received edoxaban were analyzed. The primary endpoint of this analysis was the thrombus disappearance rate at the first evaluation. Secondary endpoints included progression/recurrence of VTE, major bleeding, and D-dimer levels. The thrombus disappearance rate was 62.5%. Therefore, the null hypothesis for the primary endpoint (thrombus disappearance rate of ≤32.0%) was rejected (p = 0.00038) based on the rate of the previous study as the historical control. Recurrent VTE and major bleeding occurred in two patients each. After the start of treatment with edoxaban, a significant difference in D-dimer levels was observed (p = 0.00655). We demonstrated that a single-drug approach with edoxaban is a potential treatment option for non-acute CAT. View Full-Text
Keywords: edoxaban; DOAC; single-drug approach; cancer-associated venous thrombosis; deep-vein thrombosis; pulmonary embolism; venous thromboembolism; D-dimer edoxaban; DOAC; single-drug approach; cancer-associated venous thrombosis; deep-vein thrombosis; pulmonary embolism; venous thromboembolism; D-dimer
Show Figures

Figure 1

MDPI and ACS Style

Toshima, H.; Hisamatsu, A.; Kobayashi, K.; Ishida, H.; Shimada, K. Single-Drug Approach with Edoxaban is Effective for Resolving Non-Acute Cancer-Associated Venous Thrombosis: A Single-Arm Retrospective Analysis. Cancers 2020, 12, 1711.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop